Cargando…

Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts

[Image: see text] Pertuzumab is a monoclonal antibody that binds to HER2 and is used in combination with another HER2–specific monoclonal antibody, trastuzumab, for the treatment of HER2+ metastatic breast cancer. Pertuzumab binds to an HER2 binding site distinct from that of trastuzumab, and its af...

Descripción completa

Detalles Bibliográficos
Autores principales: Marquez, Bernadette V., Ikotun, Oluwatayo F., Zheleznyak, Alexander, Wright, Brian, Hari-Raj, Amrita, Pierce, Richard A., Lapi, Suzanne E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224522/
https://www.ncbi.nlm.nih.gov/pubmed/25058168
http://dx.doi.org/10.1021/mp500323d
_version_ 1782343367861993472
author Marquez, Bernadette V.
Ikotun, Oluwatayo F.
Zheleznyak, Alexander
Wright, Brian
Hari-Raj, Amrita
Pierce, Richard A.
Lapi, Suzanne E.
author_facet Marquez, Bernadette V.
Ikotun, Oluwatayo F.
Zheleznyak, Alexander
Wright, Brian
Hari-Raj, Amrita
Pierce, Richard A.
Lapi, Suzanne E.
author_sort Marquez, Bernadette V.
collection PubMed
description [Image: see text] Pertuzumab is a monoclonal antibody that binds to HER2 and is used in combination with another HER2–specific monoclonal antibody, trastuzumab, for the treatment of HER2+ metastatic breast cancer. Pertuzumab binds to an HER2 binding site distinct from that of trastuzumab, and its affinity is enhanced when trastuzumab is present. We aim to exploit this enhanced affinity of pertuzumab for its HER2 binding epitope and adapt this antibody as a PET imaging agent by radiolabeling with (89)Zr to increase the sensitivity of HER2 detection in vivo. Here, we investigate the biodistribution of (89)Zr-pertuzumab in HER2–expressing BT-474 and HER2–nonexpressing MDA-MB-231 xenografts to quantitatively assess HER2 expression in vivo. In vitro cell binding studies were performed resulting in retained immunoreactivity and specificity for HER2–expressing cells. In vivo evaluation of (89)Zr-pertuzumab was conducted in severely combined immunodeficient mice, subcutaneously inoculated with BT-474 and MDA-MB-231 cells. (89)Zr-pertuzumab was systemically administered and imaged at 7 days postinjection (p.i.) followed by terminal biodistribution studies. Higher tumor uptake was observed in BT-474 compared to MDA-MB-231 xenografts with 47.5 ± 32.9 and 9.5 ± 1.7% ID/g, respectively at 7 days p.i (P = 0.0009) and blocking studies with excess unlabeled pertuzumab showed a 5-fold decrease in BT-474 tumor uptake (P = 0.0006), confirming the in vivo specificity of this radiotracer. Importantly, we observed that the tumor accumulation of (89)Zr-pertuzumab was increased in the presence of unlabeled trastuzumab, at 173 ± 74.5% ID/g (P = 0.01). Biodistribution studies correlate with PET imaging quantification using max SUV (r = 0.98, P = 0.01). Collectively, these results illustrate that (89)Zr-pertuzumab as a PET imaging agent may be beneficial for the quantitative and noninvasive assessment of HER2 expression in vivo especially for patients undergoing trastuzumab therapy.
format Online
Article
Text
id pubmed-4224522
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-42245222015-07-24 Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts Marquez, Bernadette V. Ikotun, Oluwatayo F. Zheleznyak, Alexander Wright, Brian Hari-Raj, Amrita Pierce, Richard A. Lapi, Suzanne E. Mol Pharm [Image: see text] Pertuzumab is a monoclonal antibody that binds to HER2 and is used in combination with another HER2–specific monoclonal antibody, trastuzumab, for the treatment of HER2+ metastatic breast cancer. Pertuzumab binds to an HER2 binding site distinct from that of trastuzumab, and its affinity is enhanced when trastuzumab is present. We aim to exploit this enhanced affinity of pertuzumab for its HER2 binding epitope and adapt this antibody as a PET imaging agent by radiolabeling with (89)Zr to increase the sensitivity of HER2 detection in vivo. Here, we investigate the biodistribution of (89)Zr-pertuzumab in HER2–expressing BT-474 and HER2–nonexpressing MDA-MB-231 xenografts to quantitatively assess HER2 expression in vivo. In vitro cell binding studies were performed resulting in retained immunoreactivity and specificity for HER2–expressing cells. In vivo evaluation of (89)Zr-pertuzumab was conducted in severely combined immunodeficient mice, subcutaneously inoculated with BT-474 and MDA-MB-231 cells. (89)Zr-pertuzumab was systemically administered and imaged at 7 days postinjection (p.i.) followed by terminal biodistribution studies. Higher tumor uptake was observed in BT-474 compared to MDA-MB-231 xenografts with 47.5 ± 32.9 and 9.5 ± 1.7% ID/g, respectively at 7 days p.i (P = 0.0009) and blocking studies with excess unlabeled pertuzumab showed a 5-fold decrease in BT-474 tumor uptake (P = 0.0006), confirming the in vivo specificity of this radiotracer. Importantly, we observed that the tumor accumulation of (89)Zr-pertuzumab was increased in the presence of unlabeled trastuzumab, at 173 ± 74.5% ID/g (P = 0.01). Biodistribution studies correlate with PET imaging quantification using max SUV (r = 0.98, P = 0.01). Collectively, these results illustrate that (89)Zr-pertuzumab as a PET imaging agent may be beneficial for the quantitative and noninvasive assessment of HER2 expression in vivo especially for patients undergoing trastuzumab therapy. American Chemical Society 2014-07-24 2014-11-03 /pmc/articles/PMC4224522/ /pubmed/25058168 http://dx.doi.org/10.1021/mp500323d Text en Copyright © 2014 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Marquez, Bernadette V.
Ikotun, Oluwatayo F.
Zheleznyak, Alexander
Wright, Brian
Hari-Raj, Amrita
Pierce, Richard A.
Lapi, Suzanne E.
Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
title Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
title_full Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
title_fullStr Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
title_full_unstemmed Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
title_short Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
title_sort evaluation of (89)zr-pertuzumab in breast cancer xenografts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224522/
https://www.ncbi.nlm.nih.gov/pubmed/25058168
http://dx.doi.org/10.1021/mp500323d
work_keys_str_mv AT marquezbernadettev evaluationof89zrpertuzumabinbreastcancerxenografts
AT ikotunoluwatayof evaluationof89zrpertuzumabinbreastcancerxenografts
AT zheleznyakalexander evaluationof89zrpertuzumabinbreastcancerxenografts
AT wrightbrian evaluationof89zrpertuzumabinbreastcancerxenografts
AT harirajamrita evaluationof89zrpertuzumabinbreastcancerxenografts
AT piercericharda evaluationof89zrpertuzumabinbreastcancerxenografts
AT lapisuzannee evaluationof89zrpertuzumabinbreastcancerxenografts